Stephens resumed coverage on Cryoport with a new price target
$CYRX
Biotechnology: Pharmaceutical Preparations
Health Care
Stephens resumed coverage of Cryoport with a rating of Overweight and set a new price target of $13.00
Stay ahead of the competition with Standout.work - your AI-powered talent-to-startup matching platform.
| Date | Price Target | Rating | Analyst |
|---|---|---|---|
| 8/6/2025 | Sector Weight → Overweight | KeyBanc Capital Markets | |
| 8/6/2025 | $16.00 | Market Perform → Outperform | Leerink Partners |
| 7/22/2025 | $13.00 | Overweight | Stephens |
| 3/24/2025 | $10.00 | Neutral → Buy | UBS |
| 12/19/2024 | $11.00 | Buy | Guggenheim |
| 12/19/2024 | $11.00 | Buy | Canaccord Genuity |
| 8/7/2024 | $20.00 → $8.00 | Buy → Hold | Jefferies |
| 7/31/2024 | $19.00 → $15.00 | Neutral → Buy | B. Riley Securities |
LOS ANGELES, Nov. 06, 2025 (GLOBE NEWSWIRE) -- BioTech Breakthrough, a leading independent market intelligence organization that evaluates and recognizes standout life sciences and biotechnology companies, products and services around the globe, today announced that Cryoport Systems, a subsidiary of Cryoport, Inc. (NASDAQ:CYRX), a leader in temperature-controlled supply chain solutions for the Life Sciences with a focus on regenerative medicine, today announced the Safepak® Soft System 1800 has been selected as "BioServices Innovation of the Year" in the fifth annual BioTech Breakthrough Awards program. The Safepak Soft System 1800 is a secondary packaging solution that combines proprieta
Third quarter revenue increased 15% year-over-year to $44.2 millionCommercial Cell & Gene Therapy revenue increased 36% year-over-year to $8.3 millionLife Sciences Services revenue grew 16% year-over-year, including a 21% rise in BioStorage/BioServices revenue Life Sciences Products revenue grew 15% year-over-yearCompany updates full year 2025 revenue guidance of $170 to $174 millionNASHVILLE, Tenn., Nov. 4, 2025 /PRNewswire/ -- Cryoport, Inc. (NASDAQ:CYRX) ("Cryoport" or the "Company"), a leading global provider of temperature-controlled supply chain solutions for the life sciences, today announced financial results for its third quarter (Q3) and first nine months (9M) of 2025. Provided in
First Global Supply Chain Solutions Company to Achieve ISO 21973 Certification, Ensuring Highest Transport Safety, Traceability, and Integrity Standards for Cell and Gene Therapies NASHVILLE, Tenn., Oct. 30, 2025 /PRNewswire/ -- Cryoport, Inc. (NASDAQ:CYRX) ("Cryoport" or "the Company"), a global leader in temperature-controlled supply chain solutions for the life sciences, today announced that Cryoport Systems, a Cryoport company, has successfully achieved certification under ISO 21973:2020, the international standard for transportation of human cells for therapeutic use published by the International Organization for Standardization (ISO). This milestone underscores Cryoport Systems' comm
4 - Cryoport, Inc. (0001124524) (Issuer)
4 - Cryoport, Inc. (0001124524) (Issuer)
4 - Cryoport, Inc. (0001124524) (Issuer)
10-Q - Cryoport, Inc. (0001124524) (Filer)
8-K - Cryoport, Inc. (0001124524) (Filer)
SCHEDULE 13G/A - Cryoport, Inc. (0001124524) (Subject)
KeyBanc Capital Markets upgraded Cryoport from Sector Weight to Overweight
Leerink Partners upgraded Cryoport from Market Perform to Outperform and set a new price target of $16.00
Stephens resumed coverage of Cryoport with a rating of Overweight and set a new price target of $13.00
Cryoport's CRYOGENE will provide Moffitt with state-of-the-art biorepository services TAMPA, Fla. and NASHVILLE, Tenn., Jan. 14, 2025 /PRNewswire/ -- Moffitt Cancer Center, a leading National Cancer Institute-designated comprehensive cancer center, through its wholly owned subsidiary Speros FL, a 775-acre global innovation life sciences campus, and Cryoport, Inc. (NASDAQ:CYRX), a global leader in supply chain solutions for the life sciences industry, today announced a strategic collaboration that will provide CRYOGENE's state-of-the-art biorepository services to Speros in Pasco County, Florida. Cryoport's CRYOGENE business unit is a leading biorepository for the life sciences industry that i
NASHVILLE, Tenn., March 3, 2021 /PRNewswire/ -- Cryoport, Inc. (NASDAQ: CYRX) ("Cryoport" or the "Company"), a global leader in temperature-controlled supply chain solutions for the life sciences industry, today announced its Board of Directors has elected Linda Baddour as a member of the Board, effective March 15, 2021. Linda Baddour is a senior executive with over twenty years of experience in healthcare, life sciences and pharmaceuticals. "Our corporate governance underpins all that we do at Cryoport and we are delighted to strengthen our Board as we leverage our newly expanded global footprint and advanced temperature-controlled supply chain platform to spur our growth," said Jerrell She
BERKELEY, Calif. and VANCOUVER, British Columbia, Dec. 01, 2020 (GLOBE NEWSWIRE) -- BriaCell Therapeutics Corp. ("BriaCell" or the "Company") (TSX-V:BCT) (OTCQB:BCTXF), a clinical-stage biotechnology company specializing in targeted immunotherapy for advanced breast cancer, is pleased to announce that Mr. Martin Schmieg has rejoined the Company as a member of its Board of Directors. Having previously served as a member of BriaCell’s Board of Directors from 2016 to 2019, Mr. Schmieg is a “C” level executive with a diversified background in the global biotech, med-tech and pharmaceutical industries with 40 years of business experience. He currently serves as Co-Founder and CEO of ClearIt, L
Third quarter revenue increased 15% year-over-year to $44.2 millionCommercial Cell & Gene Therapy revenue increased 36% year-over-year to $8.3 millionLife Sciences Services revenue grew 16% year-over-year, including a 21% rise in BioStorage/BioServices revenue Life Sciences Products revenue grew 15% year-over-yearCompany updates full year 2025 revenue guidance of $170 to $174 millionNASHVILLE, Tenn., Nov. 4, 2025 /PRNewswire/ -- Cryoport, Inc. (NASDAQ:CYRX) ("Cryoport" or the "Company"), a leading global provider of temperature-controlled supply chain solutions for the life sciences, today announced financial results for its third quarter (Q3) and first nine months (9M) of 2025. Provided in
NASHVILLE, Tenn., Oct. 21, 2025 /PRNewswire/ -- Cryoport, Inc. (NASDAQ:CYRX) ("Cryoport" or the "Company"), a global leader in temperature-controlled supply chain solutions for the life sciences, today announced that the Company will report financial results for the third quarter ended September 30, 2025 on Tuesday, November 4, 2025 after U.S. markets close. In addition to the earnings release, a document titled "Cryoport Third Quarter 2025 in Review", providing a review of Cryoport's financial and operational performance and a general business update, will be issued at 4:05 p
Second quarter revenue increased 14% year-over-year to $45.5 millionCommercial Cell & Gene Therapy revenue increased 33% year-over-year to $8.7 millionLife Sciences Services revenue rose 21% year-over-year, including a 28% increase in BioStorage/BioServices revenue Launched strategic partnership agreement with the DHL Group; closed CRYOPDP divestitureCompany reaffirms full year 2025 revenue guidance of $165 to $172 millionNASHVILLE, Tenn., Aug. 5, 2025 /PRNewswire/ -- Cryoport, Inc. (NASDAQ:CYRX) ("Cryoport" or the "Company"), a leading global provider of temperature-controlled supply chain solutions for the life sciences, today announced financial results for its second quarter (Q2) and fir
SC 13G - Cryoport, Inc. (0001124524) (Subject)
SC 13G/A - Cryoport, Inc. (0001124524) (Subject)
SC 13G/A - Cryoport, Inc. (0001124524) (Subject)